
Novo Nordisk’s lucrative biopharma arm has stopped hemorrhaging, but growth is still a way away following years of this being the status quo. The hemophilia treatment Mim8 could speed up this process.
”It is more potent than other drugs, including Hemlibra. That means it could potentially be given in smaller volumes in better devices,” says Martin Holst Lange, executive vice president of development at Novo Nordisk.
Already a subscriber? Log in.
Read the whole article
Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
- Access all locked articles
- Receive our daily newsletters
- Access our app